Olitrace

Sodium Molybdate Dihydrate, the active ingredient in Olitrace, is a trace element supplement presented as a sterile aqueous solution for parenteral use. It provides essential minerals that support enzymatic functions in patients requiring parenteral nutrition. GNH USA supplies Olitrace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Olitrace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Olitrace is used as a multi‑trace element supplement in clinical nutrition, supporting patients who receive parenteral nutrition. - Premature infants: helps meet essential trace element requirements for growth and development. - Adult patients on long‑term parenteral nutrition: maintains adequate levels of molybdenum, zinc, chromium, copper, iron and manganese. - Post‑surgical or trauma patients: supports metabolic processes that rely on trace elements. - Patients with malabsorption syndromes: provides trace elements that are poorly absorbed orally. - Renal replacement therapy patients: assists in maintaining trace element balance during dialysis.

Olitrace may be associated with infusion‑related reactions and laboratory‑detected abnormalities.

Common Side Effects: - Mild erythema at the infusion site: transient redness that resolves without intervention. - Low‑grade fever: temporary temperature elevation that subsides spontaneously. - Transient increase in serum copper or zinc levels: laboratory finding without clinical symptoms.

Serious or Rare Side Effects: - Anaphylactic reaction: acute hypersensitivity requiring immediate medical management. - Severe hypermagnesium (if formulation contains magnesium): may cause cardiac rhythm disturbances. - Acute hemolysis: rapid destruction of red blood cells observed in rare cases. - Metabolic acidosis: significant pH imbalance requiring corrective therapy.

When using Olitrace, clinicians should assess trace element status and monitor laboratory values regularly. - Assess baseline trace element levels: obtain serum concentrations before initiating therapy. - Monitor serum concentrations: repeat testing weekly or as clinically indicated. - Adjust dosage in renal impairment: reduce or space infusions based on renal function. - Avoid concurrent high‑dose oral trace supplements: risk of excess accumulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Olitrace can interact with other medications that influence mineral balance or cause infusion reactions.

Major Interactions (Avoid): - High‑dose intravenous iron preparations: may cause excessive iron load and oxidative stress.

Moderate Interactions (Monitor Closely): - Chelating agents (e.g., deferoxamine): may reduce the effectiveness of administered trace elements. - Antacids containing aluminum or magnesium: can alter absorption if oral supplements are added. - Certain antibiotics (e.g., tetracyclines): may bind trace metals and affect their activity. - Loop diuretics: increase urinary excretion of zinc and copper, requiring closer monitoring. - Vitamin C high‑dose infusion: enhances copper absorption, potentially leading to excess levels.